Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Stages of Ovarian Low Malignant Potential Tumors
After ovarian low malignant potential tumor has been diagnosed, tests are done to find out if abnormal cells have spread within the ovary or to other parts of the body.The process used to find out whether abnormal cells have spread within the ovary or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. Certain tests or procedures are used for staging. Staging laparotomy (a surgical incision made in the wall of the abdomen to remove ovarian tissue) may be used. Most patients are diagnosed with stage I disease. The following stages are used for ovarian low malignant potential tumor: Stage IIn stage I, the tumor is found in one or both ovaries. Stage I is divided into stage IA, stage IB, and stage IC. Stage IA: The tumor is found inside a single ovary.Stage IB: The tumor is found inside both ovaries.Stage IC: The tumor is found inside one or both
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent or Persistent Ovarian Epithelial Cancer
Treatment of recurrent ovarian epithelial cancer may include the following:Chemotherapy using one or more anticancer drugs, with or without surgery.A clinical trial of surgery.A clinical trial of targeted therapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent ovarian epithelial cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - What is screening?
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early,it may be easier to treat. By the time symptoms appear,cancer may have begun to spread. Scientists are trying to better understand which people are more likely to get certain types of cancer. They also study the things we do and the ...
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062941-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Low Malignant Potential Tumors Treatment
Ovarian Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityOvarian cancer is the fifth leading cause of cancer death among women in the United States and has the highest mortality rate of all gynecologic cancers. It is estimated that 22,240 new cases of ovarian cancer will be diagnosed in the United States in 2013, and 14,030 women will die of this disease. The median age at diagnosis is 63 years. The prognosis for survival from ovarian cancer largely depends on the extent of disease at diagnosis, which is usually advanced, with only about 15% of women presenting with localized disease at diagnosis.[1,2]From 2005 to 2009, incidence rates decreased by 0.9% per year, and mortality rates decreased by 2.0% per year.Ovarian cancer is rare; the lifetime risk of being diagnosed with ovarian cancer is 1.38%.Types of Ovarian CancerThe term ovarian cancer encompasses a heterogeneous group of malignant tumors of ovarian origin that may arise from germ cells, stromal tissue, or
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage III Ovarian Germ Cell Tumors
DysgerminomasStandard treatment options:Total abdominal hysterectomy and bilateral salpingo-oophorectomy.Unilateral salpingo-oophorectomy with adjuvant chemotherapy.For patients with stage III dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy are recommended with removal of as much gross tumor as can be done safely without resection of portions of the urinary tract or large segments of the small or large bowel. Patients who want to preserve fertility may be treated with unilateral salpingo-oophorectomy if chemotherapy is to be employed.[1,2,3,4,5] (Refer to the PDQ summary on Sexuality and Reproductive Issues for more information on fertility.)Combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP) can cure the majority of such patients. In a report of results from two Gynecologic Oncology Group (GOG) trials, 19 of 20 patients with incompletely resected tumors who were treated with BEP or cisplatin, vinblastine, and bleomycin (PVB) were
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Ovarian Germ Cell Tumors
For more information from the National Cancer Institute about ovarian germ cell tumors, see the following:Ovarian Cancer Home PageDrugs Approved for Ovarian CancerFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Ovarian Cancer Screening
Tests are used to screen for different types of cancer.Some screening tests are used because they have been shown to be helpful both in finding cancers early and in decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer. Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, finding and treating the disease at an early stage may result in a better chance of recovery.There is no standard or routine screening test for ovarian cancer.Screening for ovarian cancer has not been proven to decrease the death rate from the disease.Screening for ovarian cancer is under study and
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Early-Stage Ovarian Low Malignant Potential Tumors
The value of complete staging has not been demonstrated for early-stage cases, but the opposite ovary should be carefully evaluated for evidence of bilateral disease. Although the impact of surgical staging on therapeutic management is not defined, in a study, 7 of 27 patients with presumed localized disease were upstaged following complete surgical staging. In two other studies, 16% and 18% of patients with presumed localized tumors of low malignant potential were upstaged as a result of a staging laparotomy.[2,3] In one of these studies, the yield for serous tumors was 30.8% compared with 0% for mucinous tumors. In another study, patients with localized intraperitoneal disease and negative lymph nodes had a low incidence of recurrence (5%), whereas patients with localized intraperitoneal disease and positive lymph nodes had a statistically significantly higher incidence of recurrence (50%).In early-stage disease (stage I or II), no additional treatment is indicated for a
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I and Stage II Ovarian Epithelial Cancer Treatment
Treatment options:If the tumor is well differentiated or moderately well differentiated, surgery alone may be adequate treatment for patients with stage IA and IB disease. Surgery should include hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Additionally, the undersurface of the diaphragm should be visualized and biopsied; pelvic and abdominal peritoneal biopsies and pelvic and para-aortic lymph node biopsies are required and peritoneal washings should be obtained routinely. In selected patients who desire childbearing and have grade I tumors, unilateral salpingo-oophorectomy may be associated with a low risk of recurrence.If the tumor is grade III, densely adherent, or stage IC, the chance of relapse and death from ovarian cancer is as much as 30%.[3,4,5,6] Clinical trials evaluating the following treatment approaches have been performed:Intraperitoneal P-32 or radiation therapy.[1,7,8]Systemic chemotherapy based on platinums alone or in combination with